| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.5 | 1.5 |
| Gross profit | 1.3 | 1.2 |
| Profit before tax | -0.9 | -1.0 |
| Net income | -0.9 | -1.0 |
| EPS (diluted, $ a share) | $-4.01 | $-1.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -4.3% |
|---|---|
| Gross margin | 90.3% |
| Operating margin | -55.3% |
10-Q filed with the SEC, NASDAQ: BKYI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bio Key International Inc: key numbers
- Share price
- $2.09Close, Nov 16
- Market cap
- $4.25M
- Shares outstanding
- 2.04MLatest SEC cover page
- Sector
- Technology
- Industry
- Services-Prepackaged SoftwareSIC 7372
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bio Key International Inc
All →BIO-key International Earnings Call: Key Takeaways
Bio-Key is pivoting to a high-margin software model, achieving 90% gross margins and debt-free status while leveraging Middle East expansion and agentic AI authentication.
- Call
- Nov 13, 2026, 10:00 AM ET
Bio Key International Financial Results
BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.
- Term
- Q3 2026
“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”
Mike DePasquale, CEO
“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”
Mike DePasquale, CEO
Bio Key International Shareholder Meeting
BIO-key International reported the final voting results from its 2026 Annual Meeting of Stockholders, which concluded on October 30, 2026. Stockholders approved Proposal 4, authorizing the issuance of up to 1,236,668 shares of common stock upon the exercise of warrants from an August 2026 inducement transaction to comply with Nasdaq Listing Rule 5635(d).
Bio Key International Shareholder Meeting
BIO-key International held its reconvened 2026 Annual Meeting of Stockholders on October 2, 2026, where shareholders elected five directors, ratified M&K CPAs, PLLC as auditors, and approved executive compensation on an advisory basis. The meeting was further adjourned until October 30, 2026, to allow more time for stockholders to vote on Proposal 4 regarding the issuance of common stock upon the exercise of warrants.
Bio Key International Debt Financing Update with Streeterville Capital, LLC
BIO-key International entered into exchange agreements with Streeterville Capital to settle the remaining $416,315.80 balance of a 2025 secured promissory note. The company partitioned the debt into four new notes and immediately exchanged them for 247,805 shares of common stock. As a result of these transactions, the original note has been paid in full.
- Counterparty
- Streeterville Capital, LLC